Anthony Y. Sun, M.D. served as the CEO of Zentalis Pharmaceuticals from 2014 until May 2022. He has an impressive background that combines medicine and business. With an M.D. from the renowned Mayo Clinic Medical School, Dr. Sun has significant...
Anthony Y. Sun, M.D. served as the CEO of Zentalis Pharmaceuticals from 2014 until May 2022. He has an impressive background that combines medicine and business. With an M.D. from the renowned Mayo Clinic Medical School, Dr. Sun has significant expertise in the life sciences. Before leading Zentalis, he held various positions, including being a partner at Aisling Capital, where he invested in life science companies. He was also involved with the Perseus-Soros BioPharmaceutical Fund, providing him a good mix of clinical and financial insight. In 2021, his total compensation was around $5.9 million, reflecting his key role in guiding the company through vital developments in its drug pipeline. Dr. Sun is known for making strategic moves, including a notable industry collaboration with Tempus for improving cancer therapies. His work with Zentalis has escalated the company’s profile in oncology, aiming to create innovative treatments across various cancer types. After his tenure, Dr. Sun is continuing to impact the industry and serve on multiple boards, proving his importance in the life sciences sector.